Tiny RNAs as new potential biomarkers for gammaherpesvirus-driven neurological and central nervous system diseases

微小RNA作为伽马疱疹病毒驱动的神经和中枢神经系统疾病的新潜在生物标志物

基本信息

  • 批准号:
    10727761
  • 负责人:
  • 金额:
    $ 23.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-05-10 至 2025-04-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Epstein-Barr virus (EBV) is known to damage the brain and central nervous system directly and indirectly through infected lymphocytes. These viruses are latent in healthy conditions but reactivate in immunocompromised individuals with severe consequences. Meanwhile, increasingly diverse literature has established that microRNAs (miRNAs) are extensively engaged in typical brain development, function, and dysfunction. In humans, 20~23- nucleotide (nt) miRNAs are loaded into four Argonaute (AGO) proteins, forming RNA-induced silencing complexes (RISCs) to repress the translation of mRNAs complementary to their miRNAs. Thus, proper gene regulation by miRNAs is indispensable for generating the neurological system, and their atypical expression patterns reflect the pathogenesis of neuronal diseases. Since miRNAs are known to circulate in serum, plasma, and other bodily fluids, they are used as biomarkers for diagnosing many diseases. In this context, we recently discovered that AGO- associated miRNAs are trimmed to 14-nt or shorter tiny RNAs (tyRNAs) by three 3′→5′ exonucleases: interferon- stimulated gene 20 kDa (ISG20), three prime repair exonuclease 1, and enhanced RNAi 1. ISG20 is highly expressed during EBV replication. Notably, our dual-luciferase reporter assay demonstrated that 14-nt tyRNAs no longer retain gene-silencing activity. These results suggest that viral infection globally converts miRNAs to tyRNAs, thereby making the gene expression drastically different. According to PubMed, the study of miRNAs has steadily increased, and more than 200,000 papers have already been published. In contrast, there have only been about 10 papers discussing tyRNAs, including our recent work, which demonstrates that little is known about tyRNAs. With the following two specific aims, we will determine the tyRNAs in the four different stages of EBV-infected cells: 1) no infection, 2) de novo infection, 3) latency, and 4) lytic reactivation (Aim 1). In addition, we will validate the hypothesis that the herpesvirus infection enhances tyRNA generation in neurodevelopmental disorder patients whose AGO has specific single-point mutations (Aim 2). The successful outcome of the proposed study will provide the first comprehensive data sets of tyRNAs as new potential biomarkers. The long-term goal of this study is to provide a foundation to establish a new frontier in understanding how herpesvirus infection generates tyRNAs and thus dysregulates gene expression. Obtaining the comprehensive profile of tyRNAs in the proposed project is an essential first step to proceeding towards a deeper study. The determined tyRNAs are expected to serve as biomarkers and make previously identified miRNA biomarkers more informative.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kotaro Nakanishi其他文献

Kotaro Nakanishi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kotaro Nakanishi', 18)}}的其他基金

Structural and molecular basis for cityRNA (cleavage-inducing tiny RNA)-directed RNA cleavage by AGO3
AGO3 指导的 cityRNA(切割诱导微小 RNA)切割 RNA 的结构和分子基础
  • 批准号:
    10582158
  • 财政年份:
    2020
  • 资助金额:
    $ 23.22万
  • 项目类别:
Structural and molecular basis for cityRNA(cleavage-inducing tiny RNA)-directed RNA cleavage by AGO3
AGO3 指导的 cityRNA(切割诱导微小 RNA)切割 RNA 的结构和分子基础
  • 批准号:
    10034828
  • 财政年份:
    2020
  • 资助金额:
    $ 23.22万
  • 项目类别:
Structural and molecular basis for cityRNA(cleavage-inducing tiny RNA)-directed RNA cleavage by AGO3
AGO3 指导的 cityRNA(切割诱导微小 RNA)切割 RNA 的结构和分子基础
  • 批准号:
    10426117
  • 财政年份:
    2020
  • 资助金额:
    $ 23.22万
  • 项目类别:
Structural and molecular basis for cityRNA(cleavage-inducing tiny RNA)-directed RNA cleavage by AGO3
AGO3 指导的 cityRNA(切割诱导微小 RNA)切割 RNA 的结构和分子基础
  • 批准号:
    10213789
  • 财政年份:
    2020
  • 资助金额:
    $ 23.22万
  • 项目类别:
Structural and molecular basis for cityRNA(cleavage-inducing tiny RNA)-directed RNA cleavage by AGO3
AGO3 指导的 cityRNA(切割诱导微小 RNA)切割 RNA 的结构和分子基础
  • 批准号:
    10647680
  • 财政年份:
    2020
  • 资助金额:
    $ 23.22万
  • 项目类别:
Target specificity of human RNA-induced silencing complex
人RNA诱导的沉默复合物的靶标特异性
  • 批准号:
    9980454
  • 财政年份:
    2017
  • 资助金额:
    $ 23.22万
  • 项目类别:
Target specificity of human RNA-induced silencing complex
人RNA诱导的沉默复合物的靶标特异性
  • 批准号:
    10522487
  • 财政年份:
    2017
  • 资助金额:
    $ 23.22万
  • 项目类别:
Target specificity of human RNA-induced silencing complex
人RNA诱导的沉默复合物的靶标特异性
  • 批准号:
    10237195
  • 财政年份:
    2017
  • 资助金额:
    $ 23.22万
  • 项目类别:
Target specificity of human RNA-induced silencing complex
人RNA诱导的沉默复合物的靶标特异性
  • 批准号:
    10687141
  • 财政年份:
    2017
  • 资助金额:
    $ 23.22万
  • 项目类别:
Target specificity of human RNA-induced silencing complex
人RNA诱导的沉默复合物的靶标特异性
  • 批准号:
    9368173
  • 财政年份:
    2017
  • 资助金额:
    $ 23.22万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 23.22万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 23.22万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 23.22万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.22万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 23.22万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 23.22万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 23.22万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 23.22万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 23.22万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 23.22万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了